* FY26 Pre-sales Guidance: INR 6,000 crores, targeting 15-20% growth. * H2 FY26 New Project Launch Gross Development Value (GDV): INR 9,500 crores. * Cumulative Pre-sales Target by FY28: INR 21,000 crores (15-20% CAGR). * Annuity Rental Income Potential (next 5 years): Over INR 700 crores. * Expected EBITDA Margins: 40-45% for
* Target FY26 Pre-Sales: INR 6,000 crores, indicating 15-20% growth. * Cumulative Pre-Sales by FY28: Targeted INR 21,000 crores. * New Project Launches (H2 FY26): INR 9,500 crores Gross Development Value (GDV). * Annuity Rental Income Potential: Over INR 700 crores within the next 5 years. * Residential Project EBITDA Margins: Ranges
Key Facts * Astra Microwave Products Limited announced the release of the audio recording for its Q1 and FY26 financial results conference call. * The conference call was hosted on August 14th, 2025. * The primary purpose of the call was to discuss the financial results for the first quarter and the full
Key Facts * Q1 & FY26 Results Conference Call was held on August 14, 2025. * Audio recording of the conference call is now available on the company’s website. * This announcement document serves to inform stakeholders about the audio’s availability. * Specific sales and margin guidance details are not provided within
Key Facts * Audio recording of the Q1 & FY26 results conference call released. * Call held on August 14, 2025, discussing financial results and future outlook. * Outlook for Sales: Specific figures and commentary are available in the released audio recording. * Outlook for Margin: Detailed discussions on margin expectations are part of
* Sales Outlook: Biocon projects "strong double-digit growth" for its Generics business in FY26, driven by new product launches like Liraglutide and Semaglutide. Biosimilars anticipate "accelerated growth" from key product launches (Yesintek, Denosumab), with the CRDMO segment seeing "favourable demand trends." Insulin manufacturing capacity is
Key Facts on Outlook: * Sales Outlook: Biocon anticipates accelerated growth across Biosimilars, CRDMO, and Generics segments in FY26. Generics specifically targets double-digit growth for the full year, propelled by multiple planned product launches. Biosimilars are set to build momentum through recent approvals and market penetration of products like Yesintek, Aspart,
* Generics business projected for strong double-digit growth in FY26, driven by multiple product launches. * Biosimilars anticipate accelerated growth, fueled by recent successful launches like Yesintek and upcoming approvals such as Denosumab. * Overall gross margins and EBITDA margins are expected to improve due to new product introductions and operational leverage. * Normalized
* Sales Outlook: Targeting 30-35% growth for the next three years, aiming for INR 2,500 crore turnover. * Margin Outlook: Expecting PAT margins to rise from ~10% to 17-18% overall, with the new manufacturing segment PAT exceeding 24%. * Capacity Expansion: New R-32 manufacturing plant in Rajasthan (INR 200+ crore investment, 10,
Key Facts on Outlook: * Targeting 30-35% annual sales growth over the next three years. * Anticipating a rise in average PAT margins to 17-18%, up from current 9-11%. * Launching a new 10,000-ton R-32 manufacturing plant in Rajasthan by mid-2026, projected to add significant revenue. * Khalapur and Mambattu facilities, focusing on
* Target 30-35% growth over the next three years, aiming for INR 2,500 crore turnover by 2029. * Expected PAT margins from new manufacturing to exceed 24%; blended PAT to reach 17-18% (up from current ~10%). * New R-32 manufacturing plant in Rajasthan (INR 200+ crore project) operational by mid-2026, boosting backward
Key Facts on Outlook: * Formal notification of KRBL Limited's Q1 FY2026 earnings call transcript release. * Transcript covers Unaudited Financial Results for Q1 ended June 30, 2025. * Detailed guidance on sales and margin outlook is contained within the full earnings call transcript. KRBL Limited recently announced the release of